Literature DB >> 25496369

Clinical, biochemical and histological differences between HIV-associated NAFLD and primary NAFLD: a case-control study.

I Vodkin1, M A Valasek, R Bettencourt, E Cachay, R Loomba.   

Abstract

BACKGROUND: There are limited data regarding the clinical, biochemical and liver histological characteristics of patients with HIV-associated nonalcoholic fatty liver disease (NAFLD), and whether this entity differs in presentation and severity from primary NAFLD AIM: To examine the clinical and histological differences between HIV-associated NAFLD and primary NAFLD.
METHODS: This is a cross-sectional, case-control study comparing patients with HIV-associated NAFLD vs. patients with primary NAFLD. HIV-infected patients were identified from a database of consecutive liver biopsies performed at the University of California at San Diego, over a 13-year period. HIV-infected patients with biopsy-proven NAFLD were selected as cases, after exclusion of other causes of liver disease and hepatic steatosis. Age-sex-matched controls with biopsy-proven primary NAFLD were randomly identified from the same pathology database. All biopsies underwent a standardised, detailed, histological research evaluation by a liver pathologist who was blinded to clinical and case-control status.
RESULTS: Compared to age-sex-matched patients with primary NAFLD (n = 33), patients with HIV-associated NAFLD (n = 33) had significantly higher mean aspartate aminotransferase (P < 0.001), alanine aminotransferase (P < 0.001), alkaline phosphatase (P = 0.003) and serum triglycerides (P = 0.024). Similarly, compared to age-sex-matched primary NAFLD, patients with HIV-associated NAFLD had significantly higher rates of definite steatohepatitis (37% vs. 63%, P = 0.04), and more features of liver injury, including lobular inflammation (<0.001) and acidophil bodies (<0.001).
CONCLUSION: Compared to age-sex-matched primary NAFLD, HIV-associated NAFLD has increased severity of liver disease and a higher prevalence of NASH.
© 2014 John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2014        PMID: 25496369     DOI: 10.1111/apt.13052

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  37 in total

Review 1.  Novel Approaches to Targeting Visceral and Hepatic Adiposities in HIV-Associated Lipodystrophy.

Authors:  Phyllis C Tien
Journal:  Curr Atheroscler Rep       Date:  2015-12       Impact factor: 5.113

2.  Comparative diagnostic accuracy of magnetic resonance elastography vs. eight clinical prediction rules for non-invasive diagnosis of advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease: a prospective study.

Authors:  J Cui; B Ang; W Haufe; C Hernandez; E C Verna; C B Sirlin; R Loomba
Journal:  Aliment Pharmacol Ther       Date:  2015-04-15       Impact factor: 8.171

3.  Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.

Authors:  Takara L Stanley; Lindsay T Fourman; Meghan N Feldpausch; Julia Purdy; Isabel Zheng; Chelsea S Pan; Julia Aepfelbacher; Colleen Buckless; Andrew Tsao; Anela Kellogg; Karen Branch; Hang Lee; Chia-Ying Liu; Kathleen E Corey; Raymond T Chung; Martin Torriani; David E Kleiner; Colleen M Hadigan; Steven K Grinspoon
Journal:  Lancet HIV       Date:  2019-10-11       Impact factor: 12.767

Review 4.  Obesity and Weight Gain in Persons with HIV.

Authors:  Samuel S Bailin; Curtis L Gabriel; Celestine N Wanjalla; John R Koethe
Journal:  Curr HIV/AIDS Rep       Date:  2020-04       Impact factor: 5.071

5.  Simtuzumab treatment of advanced liver fibrosis in HIV and HCV-infected adults: results of a 6-month open-label safety trial.

Authors:  Eric G Meissner; Mary McLaughlin; Lindsay Matthews; Ahmed M Gharib; Bradford J Wood; Elliot Levy; Ralph Sinkus; Kimmo Virtaneva; Dan Sturdevant; Craig Martens; Stephen F Porcella; Zachary D Goodman; Bittoo Kanwar; Robert P Myers; Mani Subramanian; Colleen Hadigan; Henry Masur; David E Kleiner; Theo Heller; Shyam Kottilil; Joseph A Kovacs; Caryn G Morse
Journal:  Liver Int       Date:  2016-07-06       Impact factor: 5.828

Review 6.  The Pathogenesis of Liver Disease in People Living With Human Immunodeficiency Virus: The Emerging Role of the Microbiome.

Authors:  Ani Kardashian; Marion G Peters; Phyllis C Tien; Jennifer C Price
Journal:  Clin Liver Dis (Hoboken)       Date:  2020-02-25

Review 7.  Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) in HIV.

Authors:  Jürgen Kurt Rockstroh
Journal:  Curr HIV/AIDS Rep       Date:  2017-04       Impact factor: 5.071

Review 8.  Inflammation and Metabolic Complications in HIV.

Authors:  Kassem Bourgi; Celestine Wanjalla; John R Koethe
Journal:  Curr HIV/AIDS Rep       Date:  2018-10       Impact factor: 5.071

Review 9.  NAFLD and HIV: Do Sex, Race, and Ethnicity Explain HIV-Related Risk?

Authors:  Subada Soti; Kathleen E Corey; Jordan E Lake; Kristine M Erlandson
Journal:  Curr HIV/AIDS Rep       Date:  2018-06       Impact factor: 5.071

10.  Statin Therapy Does Not Reduce Liver Fat Scores in Patients Receiving Antiretroviral Therapy for HIV Infection.

Authors:  Vanessa El Kamari; Corrilynn O Hileman; Pierre M Gholam; Manjusha Kulkarni; Nicholas Funderburg; Grace A McComsey
Journal:  Clin Gastroenterol Hepatol       Date:  2018-06-14       Impact factor: 11.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.